Form 4: TransMedics Group Executive Tamer Khayal Executes Stock Option and Sells Shares
SEC Form 4 Filing
Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On January 7, 2025, Tamer Khayal, Chief Commercial Officer of TransMedics Group, Inc., executed a stock option to purchase 1,083 shares of common stock at a price of $13.28 per share.
- Simultaneously, Khayal sold 1,083 shares of common stock at a weighted average price of $80.05, with individual transactions ranging from $80.00 to $80.16.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on September 6, 2023.
- Following these transactions, Khayal directly owns 20,843 shares of TransMedics Group, Inc.
- Khayal also holds 15,167 derivative securities in the form of stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of insider trading activity under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Insider trading activity is a common occurrence in publicly listed companies like TransMedics Group.
- Comparable companies such as Edwards Lifesciences, Medtronic, and Abbott Laboratories also experience similar filings related to stock options and share sales by their executives.
- The legality of these transactions hinges on compliance with SEC regulations, particularly Rule 10b5-1, which allows insiders to establish pre-arranged trading plans to avoid accusations of trading on non-public information.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2023-09-06 | Date of establishment of Rule 10b5-1 trading plan |
| 2025-01-07 | Date of stock option exercise and share sale |
| 2025-01-07 | Date of Power of Attorney execution |
| 2026-02-22 | Date the option is fully vested |
| 2032-02-22 | Expiration date of the stock option |
| 2025-01-10 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.